Request Demo
Last update 09 Dec 2025
Pembrolizumab biosimilar(Biocad)
Last update 09 Dec 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Pembrolizumab Biosimilar (Biocad CJSC), Pembrolizumab biosimilar (PK-137), 帕博利珠单抗生物类似药（Biocad CJSC） + [3] |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (02 Dec 2022), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 93660H
The sequence is quoted from: *****
Sequence Code 93670L
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Pembrolizumab biosimilar(Biocad)CTRI/2022/12/048496
A Randomized, Double-Blind Clinical Study of the Efficacyand Safety of BCD-201 (JSC BIOCAD) and Keytruda® inPatients with Unresectable or Metastatic Melanoma
NCT05986331
A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201 (JSC BIOCAD) and Keytruda? in Patients With Unresectable or Metastatic Melanoma
NCT05739006
A Multicenter, Double-Blind, Randomized Clinical Study to Evaluate the Pharmacokinetics and Safety of BCD-201 (JSC BIOCAD, Russia) and Keytruda? in Patients With Different Advanced Malignancies
100 Clinical Results associated with Pembrolizumab biosimilar(Biocad)
Login to view more data
100 Translational Medicine associated with Pembrolizumab biosimilar(Biocad)
Login to view more data
100 Patents (Medical) associated with Pembrolizumab biosimilar(Biocad)
Login to view more data
100 Deals associated with Pembrolizumab biosimilar(Biocad)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Breast Cancer | Vietnam | - | 13 Nov 2025 |
| Colorectal Cancer | Russia | 02 Dec 2022 | |
| Cutaneous Squamous Cell Carcinoma | Russia | 02 Dec 2022 | |
| Endometrial Carcinoma | Russia | 02 Dec 2022 | |
| Esophageal Carcinoma | Russia | 02 Dec 2022 | |
| Head and Neck Neoplasms | Russia | 02 Dec 2022 | |
| Hodgkin's Lymphoma | Russia | 02 Dec 2022 | |
| Melanoma | Russia | 02 Dec 2022 | |
| Microsatellite Instability cancer | Russia | 02 Dec 2022 | |
| Non-Small Cell Lung Cancer | Russia | 02 Dec 2022 | |
| Renal Cell Carcinoma | Russia | 02 Dec 2022 | |
| Transitional Cell Carcinoma | Russia | 02 Dec 2022 | |
| Triple Negative Breast Cancer | Russia | 02 Dec 2022 | |
| Uterine Cervical Cancer | Russia | 02 Dec 2022 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma, Cutaneous Malignant | Phase 3 | Russia | 18 Jul 2022 | |
| Melanoma recurrent | Phase 1 | Russia | 08 Feb 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 47 | nslwbwudoo(udbsfuqxnz) = yzfynovsye cwbhnudivs (errdaubtms ) View more | Positive | 17 Oct 2025 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free